Eclectic Associates Inc. ADV Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Eclectic Associates Inc. ADV raised its position in shares of Pfizer Inc. (NYSE:PFE) by 15.3% during the 1st quarter, Holdings Channel reports. The fund owned 13,812 shares of the biopharmaceutical company’s stock after purchasing an additional 1,838 shares during the period. Eclectic Associates Inc. ADV’s holdings in Pfizer were worth $350,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. D Orazio & Associates Inc. raised its holdings in shares of Pfizer by 5.5% during the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after acquiring an additional 391 shares in the last quarter. Lipe & Dalton raised its holdings in shares of Pfizer by 17.7% during the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company’s stock worth $71,000 after acquiring an additional 400 shares in the last quarter. Beam Wealth Advisors Inc. raised its holdings in shares of Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after acquiring an additional 401 shares in the last quarter. Providence Capital Advisors LLC raised its holdings in Pfizer by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after buying an additional 409 shares during the period. Finally, Donaldson Capital Management LLC raised its holdings in Pfizer by 1.2% during the 4th quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after buying an additional 410 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.3%

Shares of NYSE:PFE opened at $23.42 on Thursday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock has a market cap of $133.15 billion, a price-to-earnings ratio of 16.61, a PEG ratio of 0.64 and a beta of 0.58. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a 50-day moving average price of $23.02 and a 200-day moving average price of $25.02.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period last year, the business earned $0.82 earnings per share. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.34%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio is currently 124.64%.

Analyst Upgrades and Downgrades

PFE has been the topic of several research analyst reports. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Finally, Citigroup restated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.